📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-02 21:36
631 analysed today
631
Today
134,273
All-time analysed
40,194
Positive
6,287
Negative
79,947
Neutral
7,777
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
38 announcements match the current filters (relevance ≥ 5).
Demerger effective Sep 1, 2026: IGL splits into 3 entities; 1:1 and 1:3 share allotments
India Glycols Limited announced that its corporate demerger scheme became effective on September 1, 2026, with the record date set as September 2, 2026. Under the scheme, shareholders will receive 1 share of IGL Spirits Limited for every 1 IGL share held, and 1 share of Ennature Biopharma Limited for every 3 IGL shares held, alongside retaining their existing IGL shares. For FY26, the spirits & biofuels entity accounted for ₹2,801 Cr (67%) of net revenue, the retained chemicals business generated ₹1,164 Cr (28%), and the biopharma business contributed ₹246 Cr (6%). The standalone residual specialty chemicals business delivered an Adjusted EBITDA of ₹330 Cr with a 28.4% margin in FY26.
Confidence: HIGH
What changedIndia Glycols has officially split into three independent entities covering Specialty Chemicals, Spirits & Biofuels, and Biopharma/Nutraceuticals.
Why it mattersThe demerger unlocks distinct business valuations, provides pure-play operational focus, and improves targeted capital allocation across chemical, distillery, and pharma verticals.
IGL Spirits Share Ratio: 1 share for 1 IGL shareEnnature Biopharma Share Ratio: 1 share for 3 IGL sharesDemerger Effective Date: 1st September 2026IGL Spirits FY26 Net Revenue: INR 2,801 CrRetained IGL FY26 Net Revenue: INR 1,164 CrRetained IGL Adj. EBITDA Margin: 28.4%
📅 Short termShare price adjustments and listing discovery for the demerged units will drive trading volatility and price discovery over coming weeks.
📈 Long termAllows distinct peer benchmarking, tailored capital structures, and direct valuation re-rating for high-margin specialty chemicals and fast-growing spirits/biofuels divisions.
⚠ Risk flags
- Regulatory and pricing risks in the state-controlled potable spirits market.
- Execution and transition costs relating to shared assets and distinct corporate overheads.
Key Highlights
Demerger became effective on September 1, 2026, with September 2, 2026, as the record date to determine eligible shareholders.
Share entitlement ratio: 1 share of IGL Spirits Ltd for every 1 IGL share held, and 1 share of Ennature Biopharma Ltd for every 3 IGL shares held.
IGL Spirits represents the largest business with FY26 gross revenue of ₹8,416 Cr and net revenue of ₹2,801 Cr.
Retained India Glycols specialty chemicals entity posted FY26 net sales of ₹1,164 Cr and Adjusted EBITDA of ₹330 Cr (28.4% margin).
Overall consolidated EBITDA grew at a 28% CAGR over FY24–FY26 to reach ₹690 Cr.
👀 What to Watch
Track the crediting and listing dates for the newly created shares of IGL Spirits Limited and Ennature Biopharma Limited on the stock exchanges, and monitor post-demerger quarterly reporting for the three independent units.
India Glycols Demerger Effective Sep 1; Splits into 3 Separate Listed Entities
India Glycols has made its NCLT-approved Scheme of Arrangement effective from September 1, 2026, splitting the company into three distinct entities. Shareholders on the September 2, 2026 record date will receive 1 share of IGL Spirits Limited for every 1 share held, and 1 share of Ennature Bio Pharma Limited for every 3 shares held. In the June 2026 quarter, IGL Spirits generated Rs 694 crore in net revenue, India Glycols (chemicals) generated Rs 345 crore, and Ennature Bio Pharma generated Rs 90 crore. Both new entities will apply for separate listings on BSE and NSE.
Confidence: HIGH
What changedIndia Glycols has executed the demerger of its spirits/biofuel and bio-pharma/bio-polymers businesses into two separate entities, ending their subsidiary status.
Why it mattersEnables focused capital allocation, independent operational management, and distinct market valuation for each vertical (chemicals, spirits/biofuel, and nutraceuticals).
IGL Spirits Q1 Net Revenue: Rs 694 croreIndia Glycols Q1 Net Revenue: Rs 345 croreEnnature Bio Pharma Q1 Net Revenue: Rs 90 croreIGL Spirits Share Ratio: 1:1Ennature Bio Pharma Share Ratio: 1:3Record Date: September 2, 2026
📅 Short termStock will adjust for the demerger around the record date, followed by an interim period before the two new entities commence trading on BSE and NSE.
📈 Long termProvides structural clarity and allows each pure-play business to pursue tailored expansion strategies and achieve market-driven valuations.
⚠ Risk flags
- Timeline uncertainty regarding exchange listing approvals for the two demerged entities
- Regulatory and pricing controls impacting the potable spirits vertical at the state level
Key Highlights
Demerger into three distinct companies effective September 1, 2026 following ROC filing.
Share swap ratio: 1 share of IGL Spirits for every 1 IGL share, plus 1 share of Ennature Bio Pharma for every 3 IGL shares.
Business split by June 2026 quarter net revenue: IGL Spirits (Rs 694 cr), India Glycols (Rs 345 cr), and Ennature Bio Pharma (Rs 90 cr).
Record date fixed as September 2, 2026 to determine shareholder eligibility for new entity shares.
👀 What to Watch
Monitor the ex-demerger trading adjustments post the September 2, 2026 record date and track exchange listing timelines for IGL Spirits and Ennature Bio Pharma.
India Glycols Updates Board Appointments for Ennature Bio Pharma Under Demerger Scheme
India Glycols Limited has disclosed a material governance update from Ennature Bio Pharma Limited (EBL) pursuant to their ongoing Scheme of Arrangement. EBL's Board has approved the appointment of Ms. Pragya Bhartia Barwale as Managing Director for a 5-year term starting August 21, 2026, subject to shareholder approval. Additionally, Mr. U.S. Bhartia and Ms. Pooja Jhaver were appointed Non-Executive Directors, alongside four Independent Directors for 3-year terms. The filing notes that the Ennature division has achieved over ₹200 crore in annual revenue as it transitions under the scheme.
Confidence: HIGH
What changedEnnature Bio Pharma Limited constituted its Board and appointed its Managing Director and Independent Directors ahead of the corporate restructuring.
Why it mattersFormalizes the independent governance and leadership structure of the nutraceutical business unit as part of the planned corporate separation from India Glycols.
MD Term: 5 yearsIndependent Directors Appointed: 4Ennature Division Revenue: > Rs. 200 CroresIndependent Director Term: 3 years
📅 Short termAdministrative progress update on the demerger; unlikely to trigger immediate stock price movement.
📈 Long termSeparation and independent leadership for Ennature Bio Pharma may unlock value in high-margin branded nutraceutical ingredients over time.
⚠ Risk flags
- Scheme of Arrangement remains subject to necessary regulatory and shareholder approvals
- Director appointments subject to shareholder approval
Key Highlights
Ms. Pragya Bhartia Barwale appointed Managing Director of EBL for 5 years effective August 21, 2026
Four Independent Directors appointed to EBL's Board for 3-year terms ending August 20, 2029
Ennature Biopharma division historically scaled to over ₹200 crore in revenue under current leadership
Appointments are part of the Scheme of Arrangement among India Glycols, EBL, and IGL Spirits
👀 What to Watch
Monitor upcoming regulatory and shareholder voting steps regarding the corporate restructuring and demerger execution under the Scheme of Arrangement.
Demerger Record Date Set for Sep 2, 2026; 1:3 for Ennature Bio & 1:1 for IGL Spirits
India Glycols Limited has fixed September 2, 2026, as the record date for its three-way demerger scheme following NCLT approval, with the effective date set as September 1, 2026. Eligible shareholders will receive 1 equity share of Ennature Bio Pharma Limited for every 3 shares held in India Glycols (face value INR 5). Additionally, shareholders will receive 1 equity share of IGL Spirits Limited for every 1 share held in India Glycols (face value INR 5). Both resulting companies will subsequently be listed on the NSE and BSE.
Confidence: HIGH
What changedFormalised the execution timeline (Effective Date: Sep 1, 2026; Record Date: Sep 2, 2026) and share entitlement ratios for the demerger of its spirits and biopharma businesses.
Why it mattersEnables value unlocking by carving out the high-margin Potable Spirits and Nutraceuticals/Biopharma verticals into separately listed pure-play entities alongside the core bio-chemical business.
Record date: 02-Sep-2026Effective date: 01-Sep-2026Ennature Bio Pharma entitlement: 1 share for every 3 heldIGL Spirits entitlement: 1 share for every 1 heldFace value per share: INR 5
📅 Short termStock will undergo price discovery and adjustment on the ex-date; existing investors holding shares on the record date will await share credit into demat accounts.
📈 Long termProvides distinct operational focus, independent capital allocation, and market discovery for three distinct business segments (Bio-chemicals, Spirits, and Biopharma).
⚠ Risk flags
- Timeline uncertainty between the record date and the final trading commencement of the resulting companies
- Independent market valuation of spun-off entities may vary based on sector conditions
Key Highlights
Record date fixed as September 2, 2026, to determine eligibility for demerged shares
Scheme effective date established as September 1, 2026, upon RoC filing of NCLT order
Ennature Bio Pharma allotment ratio set at 1 equity share (FV INR 5) for every 3 shares held
IGL Spirits allotment ratio set at 1 equity share (FV INR 5) for every 1 share held
Both resulting entities to be listed on NSE and BSE subject to regulatory approvals
👀 What to Watch
Track the ex-date price adjustment in India Glycols shares ahead of September 2, 2026, and watch for subsequent regulatory notifications regarding the listing dates of the two newly formed entities.
India Glycols Sets Sept 2, 2026 Record Date for Demerger into 3 Listed Entities
India Glycols Limited has fixed September 1, 2026 as the Effective Date and September 2, 2026 as the Record Date for its Scheme of Arrangement post NCLT approval. Under the demerger, shareholders will receive 1 share of Ennature Bio Pharma Ltd for every 3 shares held (1:3) and 1 share of IGL Spirits Ltd for every 1 share held (1:1) in India Glycols. Both resulting companies will be listed on NSE and BSE, unbundling the spirits and biopharma businesses into separate pure-play entities.
Confidence: HIGH
What changedFormal fixation of the Effective Date (Sept 1, 2026) and Record Date (Sept 2, 2026) to execute the demerger of Ennature Bio Pharma and IGL Spirits from India Glycols.
Why it mattersEnables value unlocking by splitting India Glycols into three focused listed businesses: specialty chemicals/glycols, potable spirits, and nutraceuticals/biopharma.
Effective Date: 1st September, 2026Record Date: 2nd September, 2026Ennature Bio Pharma Share Ratio: 1:3 (1 share for every 3 shares held)IGL Spirits Share Ratio: 1:1 (1 share for every 1 share held)Face Value per Share: INR 5
📅 Short termStock will trade ex-demerger around the Record Date (Sept 2, 2026), followed by price adjustments reflecting the separated entities until new shares are credited and listed.
📈 Long termAllows distinct capital allocation, operational focus, and independent market valuations for the spirits and biopharma verticals versus the core chemicals business.
⚠ Risk flags
- Timeline risks for final listing approvals from BSE and NSE for the two resulting entities.
- Short-term liquidity fragmentation across the three separate listed stocks.
Key Highlights
Demerger Effective Date fixed as September 1, 2026 following NCLT Allahabad approval.
Record Date for share entitlement set as September 2, 2026.
Share entitlement for Ennature Bio Pharma Ltd: 1 equity share (FV ₹5) for every 3 equity shares (FV ₹5) held.
Share entitlement for IGL Spirits Ltd: 1 equity share (FV ₹5) for every 1 equity share (FV ₹5) held.
Equity shares of both resulting companies are to be listed on NSE and BSE.
👀 What to Watch
Track the ex-demerger trading date ahead of the September 2, 2026 Record Date, and monitor regulatory listing timelines and initial price discovery for Ennature Bio Pharma and IGL Spirits.
India Glycols Receives NCLT Order for Demerger of Biopharma and Spirits Units
India Glycols has received the certified true copy of the NCLT Allahabad Bench order approving its Scheme of Arrangement. Under the scheme, the Biopharma business is demerged into Ennature Bio Pharma Limited, and the Spirits & Biofuel business is demerged into IGL Spirits Limited. The appointed date is April 1, 2026, while the effective date and record date will be finalized and announced by the Board in due course. The scheme was approved overwhelmingly by equity shareholders with 4,42,48,625 votes in favor and 1 against.
Confidence: HIGH
What changedNCLT has sanctioned the composite scheme of arrangement, officially clearing the demerger of India Glycols into separate biopharma and spirits/biofuel entities.
Why it mattersThe tripartite demerger enables pure-play operational focus, distinct capital allocation, and potential value unlocking across India Glycols' biopharma, spirits/biofuel, and core chemical units.
Appointed Date: 1st April, 2026Order Date: 17.07.2026Receipt Date: 20th August, 2026Shareholder Approval (Votes): 4,42,48,625 in favour vs 1 against
📅 Short termClear regulatory approval eliminates legal overhang and sets the stage for fixing the demerger record date and corporate filing with the RoC within 30 days.
📈 Long termEnables creation of focused standalone businesses in Biopharma and Spirits, potentially driving independent valuations and clearer segment-level operating efficiencies.
⚠ Risk flags
- Execution of asset/liability segregation and listing of resulting entities
- Transferred tax liabilities and future assessments under Income Tax Act
Key Highlights
Certified true copy of NCLT order dated July 17, 2026, received by the company on August 20, 2026.
Demerger involves carving out Biopharma into Ennature Bio Pharma Ltd and Spirits & Biofuel into IGL Spirits Ltd.
Appointed Date for the Scheme of Arrangement is fixed as April 1, 2026.
Equity shareholder voting reflected 4,42,48,625 votes in favour and only 1 against, with 100% unsecured creditor approval by value.
👀 What to Watch
Track the upcoming board announcement regarding the Record Date and Effective Date to determine entitlement and timeline for shares in the resulting entities.
India Glycols Q1FY27 Call: Record EBITDA of ₹170 Cr, PAT up 32%, NCLT Approves Demerger
India Glycols released its Q1FY27 earnings conference call transcript, highlighting strong operational performance with net revenue rising 9% YoY to ₹1,130 crore and a record EBITDA of ₹170 crore (up 13% YoY). PAT grew 32% YoY supported by lower finance costs of ₹25 crore (down from ₹45 crore in Q1FY26) due to ongoing deleveraging. Segmentally, Chemicals revenue increased 20.6% to ₹362 crore, Spirits rose 5.3% to ₹361 crore, and Ennature Bio Pharma saw a breakout quarter with revenue up 65% and EBITDA up 188%. Management confirmed receipt of NCLT approval for the business restructuring and demerger, with the effective date pending.
Confidence: HIGH
What changedSubmission of the detailed Q1FY27 earnings call transcript outlining segment dynamics and confirming NCLT approval for corporate restructuring.
Why it mattersDemonstrates structural margin improvement, reduced interest burden, and progress on unlocking shareholder value through the separation of B2C spirits from B2B chemical operations.
Q1FY27 Net Revenue: ₹1130 crQ1FY27 EBITDA: ₹170 crQ1FY27 Finance Costs: ₹25 crSpirits Revenue: ₹361 crChemicals Revenue: ₹362 crBio-Fuel EBIT Margin: 8.4%
📅 Short termPositive sentiment driven by robust quarterly profitability, high operating margins across verticals, and deleveraging milestones.
📈 Long termThe demerger of the consumer spirits arm provides distinct valuation multiples and clearer capital allocation between B2B green chemistry and consumer spirits.
⚠ Risk flags
- Volatility in raw material prices (e.g. propylene oxide) and international shipping freight rates
- State-level regulatory controls on alcohol pricing and movement
Key Highlights
Q1FY27 Net Revenue grew 9% YoY to ₹1,130 crore, with gross revenue expanding 19% YoY
Record quarterly EBITDA of ₹170 crore (up 13% YoY) and PAT expansion of 32% YoY
Finance costs reduced significantly to ₹25 crore from ₹45 crore in Q1FY26 on debt repayment
Chemicals revenue rose 20.6% to ₹362 crore; Ennature Bio Pharma posted 188% EBITDA growth
NCLT approval received for business restructuring/demerger of Potable Spirits business
👀 What to Watch
Track the announcement of the record date and effective date for the Potable Spirits business demerger, alongside margin trends across the performance chemicals and IMFL segments.
India Glycols Q1 PAT Up 32% to ₹97 Cr; NCLT Approves 3-Way Demerger Plan
India Glycols (IGL) reported a strong Q1 FY27 with PAT rising 32% YoY to ₹97 Cr, supported by a 19% growth in Gross Revenue to ₹2,988 Cr. A major structural change is underway as the NCLT sanctioned a demerger on July 17, 2026, to split the company into three listed entities: Chemicals (IGL), Spirits & Bio-fuel (ISL), and Bio-pharma (EBL). Management has set aggressive 4-5 year EBITDA targets, aiming for ₹1,000 Cr in the Spirits business alone. Profitability was further boosted by a 44% reduction in finance costs due to debt reduction.
Confidence: HIGH
What changedThe company has transitioned from a single integrated entity to a sanctioned three-way demerger structure while delivering double-digit growth in EBITDA and PAT.
Why it mattersThe demerger is a value-unlocking event intended to allow independent capital allocation and attract specialized investors for the high-growth Spirits and Bio-pharma segments.
Q1 PAT Growth: 32% YoYQ1 Gross Revenue: ₹2,988 CrFinance Cost Reduction: ₹20 CrSpirits EBITDA Target (4-5 yrs): ₹1,000 CrDemerger Ratio (Spirits): 1:1Demerger Ratio (Biopharma): 1:3
📅 Short termThe stock may see positive sentiment driven by the strong Q1 earnings beat and the clarity provided by the NCLT approval for the demerger.
📈 Long termThe structural split could lead to a re-rating, especially if the Spirits business achieves its ₹1,000 Cr EBITDA target and the Chemicals business successfully shifts toward high-margin specialty products.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory risks in state-level liquor pricing
- Raw material volatility for the Bio-pharma segment
- Execution risk during the demerger and listing process
Key Highlights
Q1 FY27 PAT increased 32% YoY to ₹97 Cr, while Net Revenue grew 9% to ₹1,130 Cr.
NCLT sanctioned the demerger scheme on July 17, 2026, to create three focused listed platforms.
Finance costs dropped significantly to ₹25 Cr from ₹45 Cr in Q1 FY26, reflecting improved debt management.
Spirits business (ISL) targets ₹1,000 Cr EBITDA in 4-5 years, doubling from the FY27 expectation of ₹500 Cr.
Shareholders will receive 1 share of IGL Spirits for every 1 IGL share, and 1 share of Ennature Bio Pharma for every 3 IGL shares.
👀 What to Watch
Investors should track the regulatory timeline for the listing of the two new entities (ISL and EBL) and monitor the execution of the premiumization strategy in the Spirits segment, specifically the ramp-up of the new malt plant.
India Glycols Q1 FY27: Net Profit Rises 32% to ₹96.8 Cr; Revenue Up 19% YoY
India Glycols reported a strong performance for Q1 FY27, with consolidated revenue growing 19.4% YoY to ₹2,988.44 Cr. Net profit saw a significant jump of 32.2% YoY to ₹96.83 Cr, driven by robust growth in the Potable Spirits segment and a ₹20.60 Cr profit contribution from its Joint Venture. The Potable Spirits division remains the dominant revenue driver, contributing approximately 74% of total operations. The company continues to progress with its previously announced demerger of the Bio Pharma and Spirits & Biofuel undertakings.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, showing a substantial increase in both revenue and profitability compared to the same quarter last year.
Why it mattersThe results demonstrate strong momentum in the Potable Spirits business and the benefit of the Clariant IGL JV, helping the company maintain growth despite regulatory pricing pressures in the alcohol segment.
Consolidated Revenue (Q1 FY27): ₹2,988.44 CrConsolidated Net Profit (Q1 FY27): ₹96.83 CrPotable Spirits Revenue Share: 74.2%JV Profit Contribution: ₹20.60 CrRevenue vs TTM Revenue: ~35.4%
📅 Short termThe stock is likely to react positively in the short term due to the double-digit growth in revenue and profit, which exceeded the average quarterly performance of the previous fiscal year.
📈 Long termThe structural demerger of business units and the ongoing ₹365 Cr capex for distillery capacity expansion are key long-term drivers for specialized growth in green chemicals and spirits.
⚠ Risk flags
- High revenue concentration in the Potable Spirits segment (74%)
- Exposure to state-level regulatory changes in liquor pricing
- Vulnerability to input cost volatility in the Bio-fuel segment
Key Highlights
Consolidated Revenue from operations increased 19.4% YoY to ₹2,988.44 Cr from ₹2,503.12 Cr.
Consolidated Net Profit grew 32.2% YoY to ₹96.83 Cr compared to ₹73.25 Cr in the previous year.
Potable Spirits segment revenue surged to ₹2,218.67 Cr, up from ₹1,805.06 Cr in Q1 FY26.
Share of profit from Joint Venture (Clariant IGL) contributed ₹20.60 Cr to the consolidated bottom line.
Consolidated EPS for the quarter stood at ₹14.45, up from ₹11.83 in the year-ago period.
👀 What to Watch
Investors should monitor the execution timeline of the 'Composite Scheme of Arrangement' involving the demerger of Bio Pharma and Spirits & Biofuel units, which could lead to value unlocking. Additionally, track the ramp-up of the New Specialities Unit (NSU) and its impact on the Bio-based Specialities segment margins.
India Glycols Appoints Manoj Kumar Rai as ED & COO of IGL Spirits Subsidiary
India Glycols has appointed Manoj Kumar Rai as the Executive Director and Chief Operating Officer of its wholly-owned subsidiary, IGL Spirits Limited, for a five-year term effective August 4, 2026. This appointment is a material update related to the ongoing Scheme of Arrangement involving the company's spirits and biopharma businesses. Mr. Rai, an IIT Delhi and IIM Lucknow alumnus, brings over 27 years of experience, most recently serving as Chief Revenue Officer at Allied Blenders and Distillers Limited (ABDL). This leadership strengthening aligns with the company's strategy to scale its potable spirits portfolio and in-house brands.
Confidence: HIGH
What changedManoj Kumar Rai has been appointed as Executive Director and Key Managerial Personnel of the subsidiary IGL Spirits Limited, moving into a formal board-level role.
Why it mattersHiring a veteran from a major competitor (ABDL) to lead the spirits subsidiary indicates a serious push to transition from low-margin commodity chemicals toward high-margin branded spirits.
Term of Appointment: 5 yearsAppointee Experience: 27+ yearsTTM Revenue (Consolidated): ₹ 8443 crMarket Cap: ₹ 7391 cr
📅 Short termThe appointment is likely to be viewed positively by the market as it brings specialized leadership to a key growth vertical.
📈 Long termStructural positive if the new leadership successfully ramps up in-house brands and improves the product mix in the spirits segment over the next 2-3 years.
⚠ Risk flags
- Execution risk in a highly competitive and regulated spirits market
- Pending finalization of the Scheme of Arrangement
Key Highlights
Appointment of Manoj Kumar Rai as Additional Director and COO for a 5-year term ending August 3, 2031.
Mr. Rai brings over 27 years of industry experience, including a previous role as Chief Revenue Officer at Allied Blenders and Distillers Limited.
The appointment is a formal requirement under the Stock Exchange Observation Letters dated November 17 and 19, 2025, regarding the Scheme of Arrangement.
IGL Spirits Limited is a wholly-owned subsidiary central to the parent company's Rs 8,443 Cr TTM revenue operations.
The appointee has prior experience at major firms including Pernod Ricard India, Marico Industries, and Saregama India.
👀 What to Watch
Investors should monitor the execution of the Potable Spirits growth strategy under the new leadership and the final regulatory approval timeline for the Scheme of Arrangement.
NCLT Sanctions Demerger of Bio Pharma and Spirits & Biofuel Units
India Glycols Limited (IGL) has received formal sanction from the NCLT Allahabad Bench for its Scheme of Arrangement. The scheme involves demerging the 'Bio Pharma' undertaking into Ennature Bio Pharma Limited and the 'Spirits and Biofuel' undertaking into IGL Spirits Limited. The proposal received 100% approval from voting equity shareholders and unsecured creditors representing Rs 642.66 Cr in value. The appointed date for this structural reorganization is April 1, 2026.
Confidence: HIGH
What changedThe company has cleared the final legal hurdle (NCLT sanction) to split its business into three distinct entities: Chemicals (Remaining IGL), Bio Pharma, and Spirits & Biofuel.
Why it mattersThis is a major structural reorganization aimed at unlocking value. By separating the high-growth Spirits and specialized Bio Pharma segments from the core industrial chemical business, the company can pursue independent capital allocation and potentially achieve better market valuations for each segment.
Appointed Date: 1st April, 2026Creditor Value in Favor: Rs 64,266.50 lakhShareholder Approval: 100%TTM Revenue: Rs 8,443 CrMarket Cap: Rs 7,258 Cr
📅 Short termThe stock may see positive sentiment as the regulatory uncertainty regarding the demerger timeline is now resolved.
📈 Long termStructural re-rating is possible as the Spirits business, which often commands higher P/E multiples than industrial chemicals, becomes a standalone entity.
⚠ Risk flags
- Operational transition risks during the separation of undertakings
- Regulatory compliance across multiple new entities
Key Highlights
Appointed date for the demerger is fixed as April 1, 2026
Unsecured creditors representing Rs 64,266.50 lakh in value voted 100% in favor of the scheme
Total of 4,42,48,626 equity shares voted unanimously in favor of the restructuring
Two new resulting companies created: Ennature Bio Pharma Limited and IGL Spirits Limited
NCLT order pronounced on July 17, 2026, following the second motion petition
👀 What to Watch
Watch for the announcement of the 'Effective Date' and the specific share entitlement ratio for the new entities once the certified order is filed with the Registrar of Companies.
NCLT Sanctions Demerger of Bio Pharma and Spirits & Biofuel Units
The National Company Law Tribunal (NCLT), Allahabad Bench, has sanctioned India Glycols' Scheme of Arrangement for the demerger of two major business segments. The Bio Pharma undertaking will be transferred to Ennature Bio Pharma Limited, and the Spirits and Biofuel undertaking will be transferred to IGL Spirits Limited. This move aims to streamline operations across the company's Rs 8,443 Cr TTM revenue base. The formal order was pronounced on July 17, 2026, marking a critical legal milestone for the restructuring.
Confidence: HIGH
What changedThe company has received formal legal approval from the NCLT to split its business into three distinct entities (the parent and two new resulting companies).
Why it mattersThis restructuring allows for independent management and capital allocation for the high-growth Bio Pharma and Spirits/Biofuel segments, which are currently part of a larger conglomerate structure with 7.3% OPM.
TTM Revenue: Rs 8443 CrDistillery Capex: Rs 365 CrMarket Cap: Rs 7361 CrOrder Pronouncement Date: 17th July 2026
📅 Short termThe stock may see positive momentum as the legal uncertainty regarding the demerger timeline is resolved.
📈 Long termStructural shift to specialized entities could lead to better valuation multiples for the Bio Pharma and Spirits businesses compared to the current consolidated P/E of 25.2.
⚠ Risk flags
- Execution risk during the transition of operations to new entities
- Regulatory transfer of liquor licenses to the new Spirits entity
Key Highlights
NCLT Allahabad Bench sanctioned the demerger scheme on July 17, 2026
Bio Pharma undertaking to be demerged into Ennature Bio Pharma Limited
Spirits and Biofuel undertaking to be demerged into IGL Spirits Limited
Restructuring involves a company with TTM revenue of Rs 8,443 Cr and a market cap of Rs 7,361 Cr
Company is currently undergoing a Rs 365 Cr capex for distillery capacity enhancement
👀 What to Watch
Investors should monitor the upcoming announcement of the 'Record Date' for the allotment of shares in the two new resulting companies. Track the listing timelines for Ennature Bio Pharma and IGL Spirits to assess the value unlocking potential.
NCLT Reserves Final Order for Demerger of Bio-Pharma and Spirits Units
India Glycols Limited (IGL) has reached the final stage of its corporate restructuring, with the NCLT Allahabad Bench reserving its final order on July 2, 2026. The scheme involves demerging the Nutraceuticals business into Ennature Bio pharma Limited and the Spirits business into IGL Spirits Limited. Regulatory reports from the RoC and Official Liquidator have been filed with no adverse observations. A minor tax demand of ₹27,890 was the only point of discussion, which the company has undertaken to settle if required post-sanction.
Confidence: HIGH
What changedThe legal proceedings for the demerger have concluded; the company is now awaiting the formal judicial verdict to execute the split of its business segments.
Why it mattersThis demerger is a significant value-unlocking exercise, separating the core chemical business from the high-growth Spirits and Bio-Pharma segments, potentially leading to a re-rating of the individual businesses.
Tax Demand: ₹27,890TTM Revenue: ₹8,443 CrMarket Cap: ₹6,830 CrResulting Companies: 2
📅 Short termPositive sentiment is expected as the company nears the completion of a long-awaited restructuring process.
📈 Long termStructural significance is high as it allows for independent management and capital allocation for the Spirits and Nutraceuticals divisions, which have different margin profiles than the base chemical business.
⚠ Risk flags
- Execution risk during the transition to three separate entities
- Market volatility during the listing process of the resulting companies
Key Highlights
NCLT reserved the matter for final pronouncement on July 2, 2026, following the second motion petition.
The restructuring involves spinning off two entities: Ennature Bio pharma Limited and IGL Spirits Limited.
RoC and Official Liquidator (Uttarakhand) reports contained no adverse observations regarding the scheme.
Income Tax Department raised a negligible demand of ₹27,890, which the company is prepared to address.
India Glycols (Demerged Company) will remain in existence post-approval to fulfill any outstanding liabilities.
👀 What to Watch
Investors should monitor the exchange for the final NCLT written order, which will lead to the announcement of the record date for share entitlement in the new entities.
India Glycols Appoints Industry Veteran Manoj Kumar Rai as COO of IGL Spirits Subsidiary
India Glycols Limited has appointed Shri Manoj Kumar Rai as the Chief Operating Officer (COO) of its wholly-owned subsidiary, IGL Spirits Limited, effective July 2, 2026. Rai is a seasoned leader with 27 years of experience, most recently serving as the Chief Revenue Officer at Allied Blenders and Distillers Limited (ABDL). This strategic hire aligns with the company's goal to scale its potable spirits portfolio and premiumize its in-house brands like Zumba Lemoni and Soulmate Blu. Given the company's TTM revenue of ₹8,443 Cr and its focus on expanding distillery capacity (₹365 Cr capex), this leadership addition is significant for the spirits division's growth.
Confidence: HIGH
What changedIndia Glycols has hired a high-profile executive from a direct competitor (Allied Blenders) to lead its spirits subsidiary.
Why it mattersThe potable spirits segment is a focus for margin expansion; bringing in a veteran with deep P&L and revenue management experience is critical for competing with established players like Radico Khaitan and ABDL.
Experience of Appointee: 27 yearsTTM Revenue: ₹8,443 CrPlanned Distillery Capex: ₹365 CrEffective Date: July 2, 2026
📅 Short termSentimentally positive as it demonstrates the company's commitment to professionalizing and scaling its high-growth spirits business.
📈 Long termStructural positive; Rai's expertise in business transformation and commercial excellence could lead to better distribution and brand positioning for IGL's potable spirits.
⚠ Risk flags
- Execution risk in a highly regulated industry where state governments control pricing
Key Highlights
Appointment of Manoj Kumar Rai as COO of IGL Spirits Limited effective July 2, 2026
Rai brings over 27 years of experience from major firms including Allied Blenders and Distillers, Pernod Ricard, and Marico
Educational background includes a B.Tech from IIT Delhi and a PGDM from IIM Lucknow
The appointment targets the Potable Spirits segment, which is a key growth driver for the ₹6,660 Cr market cap company
Rai previously held the role of Chief Revenue Officer at a major industry peer (ABDL)
👀 What to Watch
Investors should monitor the pace of new brand launches and market share gains in the IMFL segment over the next 2-4 quarters to gauge the impact of this leadership change.
India Glycols FY26 PAT Jumps 26.8% to ₹293 Cr; Bio-Fuels EBIT Doubles
India Glycols Limited delivered a robust FY26 performance, with net revenue increasing 11.8% to ₹4,211 crores and PAT rising 26.8% to ₹293 crores. The Bio-Fuels segment was a standout performer, with EBIT doubling to ₹115 crores driven by India's 20% ethanol blending mandate. Operational efficiency improved significantly, as evidenced by EBITDA margins expanding 162 basis points to 15.5%. Furthermore, the company successfully deleveraged its balance sheet, bringing the debt-to-equity ratio down to 0.5x from 0.7x in FY23.
Key Highlights
FY26 EBITDA increased 24.5% YoY to ₹654 crores, with margins reaching 15.5%.
Bio-Fuels segment revenue grew 40.9% to ₹1,470 crores, while EBIT surged 103.3% to ₹115 crores.
Potable Spirits business maintained market leadership with 14.4% revenue growth to ₹1,331 crores.
Return on Capital Employed (ROCE) improved significantly to 11.9% in FY26 from 7.7% in FY23.
Chemicals segment EBIT rose 12.5% to ₹141 crores despite a 10.4% revenue decline, reflecting a shift to high-value products.
👀 What to Watch
The company's strategic shift toward premium spirits and specialty chemicals, coupled with a strengthening balance sheet, makes it a positive prospect. Investors should watch for continued execution in the Ennature Biopharma segment and global crude price trends affecting chemical competitiveness.
India Glycols Files ₹79.76 Crore Insurance Claim Recovery Against New India Assurance
India Glycols Limited has initiated legal action to recover an insurance claim of ₹79.76 Crore from The New India Assurance Co. Limited. The dispute relates to a 2020 claim for property damage, machinery breakdown, and business interruption at the company's Kashipur plant. After the insurer repeatedly repudiated the claim, India Glycols filed for Pre-Institution Mediation and Settlement before the Delhi High Court. The company believes it has a strong case on merits and is seeking the full claim amount plus interest.
Key Highlights
Initiated legal steps for recovery of ₹79.76 Crore towards material damage and loss of profit.
The claim pertains to an incident at the Kashipur Plant dating back to the year 2020.
Filed an application for Pre-Institution Mediation and Settlement before the Delhi High Court on May 21, 2026.
The claim was previously repudiated by The New India Assurance Co. Limited despite multiple representations.
Company is seeking the principal claim amount along with applicable interest.
👀 What to Watch
Investors should monitor the mediation and potential litigation outcomes, as a successful recovery of ₹79.76 Crore would represent a significant non-recurring gain for the company.
India Glycols NCLT Hearing for Demerger Postponed Due to Paucity of Time
India Glycols Limited (IGL) has reported a procedural delay in its ongoing corporate restructuring process. The NCLT Allahabad Bench was scheduled to hear the Second Motion Petition regarding the demerger of businesses into Ennature Biopharma Limited and IGL Spirits Limited on May 21, 2026. However, the hearing could not take place due to the court's time constraints, and a new date is currently awaited. This follows the initial admission of the petition on April 10, 2026.
Key Highlights
Hearing for the Scheme of Arrangement involving Ennature Biopharma and IGL Spirits was scheduled for May 21, 2026.
The NCLT Allahabad Bench postponed the matter due to paucity of time.
The petition relates to the Second Motion following the initial admission on April 10, 2026.
The next date of hearing is yet to be notified by the tribunal.
The restructuring aims to separate the biopharma and spirits businesses into distinct entities.
👀 What to Watch
Investors should view this as a routine procedural delay and continue to monitor for the next hearing date, as the demerger is a key value-unlocking event for the company.
India Glycols FY26 PAT Jumps 26.8% to ₹293 Cr; Announces Major Three-Way Demerger Plan
India Glycols (IGL) delivered a strong performance in FY26, with consolidated Net Revenue rising 11.8% to ₹4,211 Cr and PAT increasing 26.8% to ₹293 Cr. Growth was led by the Bio-Fuel segment (+40.9% YoY) and Potable Spirits (+14.4% YoY), while the company successfully reduced finance costs and doubled its cash flow from operations to ₹769 Cr. A significant value-unlocking demerger is underway to split the business into three separate listed entities focusing on Chemicals, Spirits/Bio-fuel, and Bio-pharma, with an NCLT hearing scheduled for May 21, 2026.
Key Highlights
FY26 Consolidated EBITDA grew 24.5% YoY to ₹654 Cr with margins expanding 162 bps to 15.5%.
Bio-Fuel segment revenue surged 40.9% to ₹1,470 Cr, driven by the national 20% ethanol blending program.
Potable Spirits segment reported ₹1,331 Cr revenue with a robust 21.4% EBIT margin, supported by premiumization.
Proposed demerger ratio: 1 share of Ennature Bio Pharma for every 3 IGL shares, and 1 share of IGL Spirits for every 1 IGL share.
Finance costs for Q4FY26 dropped to ₹26 Cr from ₹45 Cr YoY, reflecting significant debt reduction through internal accruals.
👀 What to Watch
The strong operational growth combined with a clear value-unlocking demerger strategy makes this a positive outlook for long-term investors. Shareholders should monitor the NCLT proceedings on May 21 for the final approval of the restructuring.
India Glycols FY26 PAT Jumps 56.5% to ₹282 Cr; Bio-Fuel Segment Revenue Surges 41%
India Glycols reported a strong financial performance for FY26, with standalone net profit rising 56.5% to ₹282.33 crore compared to ₹180.38 crore in FY25. Annual revenue from operations grew by 8.7% to reach ₹9,826.20 crore, driven largely by the Bio-Fuel and Potable Spirits segments. The Bio-Fuel segment showed exceptional growth, with revenue increasing from ₹1,043.55 crore to ₹1,469.93 crore. EBITDA margins improved significantly, with annual EBITDA rising 32.4% to ₹690.09 crore.
Key Highlights
Standalone Net Profit for FY26 increased by 56.5% YoY to ₹282.33 crore.
Revenue from operations for the full year grew 8.7% to ₹9,826.20 crore.
Bio-Fuel segment revenue surged by 40.8% YoY to ₹1,469.93 crore in FY26.
Q4 FY26 PAT saw a massive jump of 119% YoY, reaching ₹110.28 crore compared to ₹50.35 crore in Q4 FY25.
Annual Basic EPS improved significantly to ₹44.31 from ₹29.13 in the previous year.
👀 What to Watch
Investors should monitor the continued scaling of the high-growth Bio-Fuel segment and the company's ability to maintain these expanded margins. The strong bottom-line growth and improved EPS make it a positive outlook for long-term holders.
India Glycols FY26 Net Profit Surges 56% to ₹282 Cr; Q4 Profit Jumps 119% YoY
India Glycols reported a robust financial performance for FY26, with standalone annual net profit rising 56.5% to ₹282.33 crore. The fourth quarter was particularly strong, with net profit more than doubling to ₹110.28 crore compared to ₹50.35 crore in Q4FY25. Revenue growth was steady at 8.7% for the full year, reaching ₹9,826.20 crore. The Bio-Fuel segment emerged as a key growth driver, with its annual EBIT nearly doubling to ₹115.23 crore, reflecting improved operational efficiencies and market demand.
Key Highlights
Standalone Net Profit for FY26 increased by 56.5% YoY to ₹282.33 crore.
Q4 FY26 Net Profit surged 119% YoY to ₹110.28 crore from ₹50.35 crore.
Annual Revenue from Operations grew to ₹9,826.20 crore, up from ₹9,037.82 crore in FY25.
Bio-Fuel segment EBIT saw massive growth, reaching ₹115.23 crore in FY26 vs ₹56.68 crore in FY25.
Full-year Earnings Per Share (EPS) improved significantly to ₹44.31 from ₹29.13 in the previous year.
👀 What to Watch
The significant margin expansion in the Bio-Fuel segment and strong bottom-line growth make this a positive result for shareholders. Investors should maintain a positive outlook while monitoring the scalability of the Bio-based Specialities segment.
